Monday, January 16, 2017

BRIEF-AstraZeneca refines endpoints for Mystic cancer drug trial

* Expands 1st-line lung cancer immuno-oncology programme

opportunities

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)